ACE platform compounds
Pre-clinical- Indications
- Bacterial infections, Fungal infections
Company intelligence / Profile preview
Xiretsa
Santa Barbara, California, United Statesxiretsapharm.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Promising preliminary results in Klebsiella pneumoniae lung and wound infections; developing antibiotics that show low likelihood of resistance development
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Walter Reed Army Institute of ResearchChemistry Center for Combating Antibiotic Resistant Bacteria (CC4CARB)Cystic Fibrosis FoundationNational University of Singapore (NUS) Medical School
Beyond the preview
Go deeper on Xiretsa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiretsa.